What is the recommended treatment and prophylaxis for a 64-year-old woman with three episodes this year of recurrent unilateral facial erythematous rash crossing the midline and associated vertigo that improves with penicillin?

Recurrent Facial Erysipelas: Treatment and Prophylaxis

For this 64-year-old woman with three episodes of recurrent facial erysipelas this year, initiate prophylactic antibiotic therapy immediately with either monthly intramuscular benzathine penicillin 1.2 million units or oral penicillin V 1 gram twice daily, continuing indefinitely while predisposing factors persist.

Acute Episode Management

When treating active episodes:

• Penicillin remains the treatment of choice for erysipelas, given either parenterally or orally depending on severity 1
• Oral penicillin V 1 gram twice daily is appropriate for mild-to-moderate cases 2
• For severe presentations requiring hospitalization, use intravenous benzyl penicillin 1
• Treatment duration: 5-10 days (5 days is as effective as 10 days for uncomplicated cases) 1

Alternative agents if penicillin-allergic: first-generation cephalosporins, clindamycin, or erythromycin (though macrolide resistance is increasing) 1

Prophylaxis Indication and Regimen

Your patient clearly meets criteria for prophylaxis: She has experienced 3-4 episodes within one year, which exceeds the threshold for initiating preventive therapy 3.

Prophylactic Options (choose one):

1. Intramuscular benzathine penicillin G 1.2 million units monthly 1

   • Most recent research supports once-every-3-weeks dosing (10 doses over 30 weeks) with 82.6% completion rate and significant reduction in recurrence (incidence rate ratio 0.20) 4
   • Higher cumulative doses correlate with better prevention 5

2. Oral penicillin V 1 gram twice daily 1

   • Requires patient adherence but avoids injections
   • Equally effective when taken consistently

3. Oral erythromycin 250 mg twice daily (alternative if penicillin-allergic) 1

Duration: Continue prophylaxis indefinitely as long as predisposing factors persist 3. The 2014 IDSA guidelines emphasize that infections may recur once prophylaxis is discontinued 3.

Critical Predisposing Factors to Address

Each attack causes cumulative lymphatic damage, increasing future recurrence risk 1. Address these factors aggressively:

• Tinea pedis or interdigital toe web maceration (streptococci reservoir in 68-69% of lower extremity cases) 1
• Lymphedema or venous insufficiency
• Skin barrier integrity: keep skin well-hydrated with emollients to prevent cracking 1
• Obesity (particularly when combined with local risk factors) 4
• Consider elevation, compression stockings, or diuretic therapy if edema present 1

Important Clinical Caveats

The vertigo symptom is unusual for typical erysipelas and warrants consideration of:

• Concurrent viral illness
• Medication side effect (though penicillin rarely causes vertigo)
• Unrelated vestibular pathology
• This does not change the erysipelas management but should be evaluated separately

Guideline strength: The prophylaxis recommendations carry moderate-quality evidence (B-II rating) 1. Two randomized trials demonstrated substantial reduction in recurrences with twice-daily oral penicillin or erythromycin 3, though one observational study found monthly benzathine penicillin beneficial only in patients without identifiable predisposing factors 3.

Common pitfall: Clinicians often fail to initiate prophylaxis despite clear indications, leading to progressive lymphatic damage and increasingly frequent episodes. With three episodes already this year, your patient is at high risk for developing chronic lymphedema if prophylaxis is not started promptly 1.

The 2014 IDSA guidelines explicitly recommend prophylaxis for patients with 3-4 episodes per year despite treating predisposing factors 3, making this a straightforward indication in your patient.